Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroethanol SCHEMBL3132268 | 0.79 | — | — | |
| Alcohol SCHEMBL48558 | 0.75 | ALDH1A1 (0.55) | CYP1A2CYP2C9HPGDMAPK1HIF1A | |
| Trifluoroethanol SCHEMBL3396675 | 0.75 | — | — | |
| Trifluoroethanol SCHEMBL28192499 | 0.75 | MEN1 (0.36) | — | |
| Trifluoroethanol SCHEMBL4869 | 0.75 | — | — | |
| Trifluoroethanol SCHEMBL8952016 | 0.75 | — | — | |
| Trifluoroethanol SCHEMBL5733186 | 0.73 | ALDH1A1 (0.39) | HSD17B10 | |
| Deanol SCHEMBL6665643 | 0.73 | MEN1 (0.35) | — | |
| Tromethamine SCHEMBL4938995 | 0.73 | MEN1 (0.59) | — | |
| Alcohol SCHEMBL974601 | 0.72 | ALDH1A1 (0.50) | CYP1A2CYP2C9HPGDMAPK1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3208269-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-15 | — | — | EP | disclosed |
| CN-109962293-A | Non-aqueous electrolyte for lithium ion cell, lithium ion battery and application | 李金铃 | 2019-07-02 | — | — | CN | disclosed |
| CN-109818061-A | Non-aqueous electrolyte for lithium ion cell, lithium ion battery and application | 李金铃 | 2019-05-28 | — | — | CN | disclosed |
| EP-3208269-A1 | INHIBITORS OF C-FMS KINASE | Janssen Pharmaceutica N.V. (BE) | 2017-08-23 | — | — | EP | disclosed |
| EP-2215079-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-14 | — | — | EP | disclosed |
| CN-101889009-B | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-10-29 | — | — | CN | disclosed |
| US-8497376-B2 | 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-07-30 | — | — | US | disclosed |
| CN-101889009-A | The c-fms kinase inhibitor | JANSSEN PHARMACEUTICA NV | 2010-11-17 | — | — | CN | disclosed |
| EP-2215079-A1 | INHIBITORS OF C-FMS KINASE | Janssen Pharmaceutica N.V. (BE) | 2010-08-11 | — | — | EP | disclosed |
| US-20090105296-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-23 | — | — | US | disclosed |
| WO-2009052237-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105296-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | CYP1A2 3278/4885CYP2C9 1815/4885HPGD 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.